

October 2023

Investment Sheet Topadur Pharma AG

Information on the capital increase of CHF 22.0 million
including convertible bonds CHF 3.0 million for Q3 2023

About Topadur Pharma AG

Topadur Pharma AG is a Swiss biopharmaceutical clinical stage start-up company based in Schlieren, Zurich. The company was founded in 2015 by experts with decades of experience in pharmaceutical R&D. Topadur develops innovative treatments (DualTOP™ technology platform) for aging-related diseases such as chronic wounds, diabetic retinopathy, colorectal cancer, alopecia and pulmonary fibrosis. Topadur is committed to bringing patients innovative/disruptive, effective, safe medical solutions.

Investment strategy

Topadur has an extensive portfolio of drugs in different stages of development. The primary business strategy is to develop and market TOP-N53, a drug for treating a rare disease, thus facilitating a market launch by the drug regulatory authorities. For the other drugs in the portfolio, an early partnership (out-licensing) with globally operating pharmaceutical companies is aimed. Topadur investors can expect a significant return on investment (ROI) from the long-term, sustainable business strategy approved by the Board of Directors, the mature and patented product pipeline and the upcoming IPO.

Financing Strategy

The funds from the Series C-2 financing round will be used as follows: Wound healing products (CHF 6-8 million), diabetic retinopathy (CHF 2-3 million), colorectal cancer (CHF 2-3 million), alopecia (CHF 1 million) and to expand the pipeline (CHF 1-2 million) by the end of 2024.

Exit Strategy

IPO (2024/25) with an expected company value of over CHF 500M.

Investment Case

- High-value creation through an attractive product pipeline with potential market volumes in the billions of dollars
- Highly experienced management and board team with longstanding expertise in R&D, management and commercialization of pharmaceutical products
- Successful completion of Phase 1 study of TOP-N53 with good tolerability and efficacy profile in digital ulcer, Phase 2a finishing in Q1 2024.
- Orphan drug designation (ODD) for TOP-N53, with a fast-track market access and 10-year market exclusivity

Portfolio Development

- **TOP-N53** Wound healing in digital ulcers in scleroderma patients (orphan drug status) and chronic diabetic foot ulcers
- **TOP-V122** Diabetic retinopathy, colorectal cancer, lung fibrosis
- **TOP-M119** Medical cosmetics for the treatment of alopecia.

Further Information

Issuer	Topadur Pharma AG
Auditors	KPMG, Zürich
Inception	10 March 2015
Company ID	CHE-481.951.668
Business year	1. January-31. December
Annual report	Annually per 31.3.
Special provisions	Sale of shares as stated in the shareholder agreement until the expected IPO
Price per share	CHF 270 (CHF 230 and CHF 235 for 3 million convertible bond)
Current valuation	CHF 64 Mio.
Expected IPO	2024/25
Minimum subscription	CHF 150'000.00
Subscription deadline	30.9.2023
Allocation of shares	Conversion of bond into shares 10/23

Product pipeline

Topadur has developed the DualTOP™ technology platform consisting of dual-acting drugs that increase cellular cGMP levels to stimulate microcirculation, correct disease-related circulatory disorders, and promote cell-cell communication and tissue regeneration. DualTOP™ drugs are locally administered, locally active making them safe therapies. **TOP-N53**: This was the first drug candidate selected in 2015. TOP-N53 is in clinical development for digital ulcers with the phase 1 trial successfully completed with both endpoints, tolerability and efficacy markers, met. Completion for the phase 2a patient clinical trial is planned for Q1 2024. Due to the ODD, accelerated access to the scleroderma market, valued at USD 1.5 billion in 2021, is expected. The compound is also predicted to be effective in diabetic patients with chronic foot ulcers (DFU), which is a significant unmet medical need. The existing market has been valued at USD 8.7 billion. In animal wound healing models, TOP-N53 showed unprecedented efficacy and tolerability. **TOP-V122**: This is the most potent dual-acting drug candidate in our pipeline to date. Our first indication for this drug candidate is diabetic retinopathy, an indication with enormous unmet medical need. A preclinical proof-of-concept study is ongoing, with first results expected by the end of 2023. The existing market has been valued at USD 7.6 billion. Given the unique efficacy of the compound, there is significant potential for additional indications. Colon cancer is one of the most important of these for which a preclinical proof of concept study is also ongoing. The existing market was valued at USD 18 billion. Given the high and unique effectiveness of this product, it has considerable potential for additional indications, such as lung fibrosis and pulmonary arterial hypertension. We expect TOPV122 to have disease-modifying effects, based on the angiogenetic activity when applied locally to lung tissues. Currently, a preclinical proof of concept study is ongoing with


first results expected by the end of 2023. The existing lung fibrosis market was valued at USD 2.2 billion. **TOP-M119**: is being developed for the treatment of alopecia. This drug candidate has been shown to be effective in promoting hair growth in an animal model of alopecia. Compared to minoxidil, the only approved topically applicable drug in this area, TOP-M119 shows more than 1000-fold higher efficacy. The existing market was valued at USD 2.6 billion.

Awards from TOPADUR Pharma AG


- TOP 100 Swiss Scale-ups 2022, 2023
- TOP 100 Swiss Scale-ups 2020
- TOP 100 Swiss Startups 2019
- Winner ED Dong Sheng Cup 2018
- Winner SEF Award 2018
- TOP 100 Schweizer Startups 2018
- Winner Venture Leaders China 2018
- Winner Swiss Innovation Challenge 2017
- TOP 100 Swiss Startups 2017
- Winner IMD Startup 2016
- CTI-Label-Unternehmen 2016
- TOP 100 Swiss Startups 2016
- Winner Venture Leaders Life Science 2016
- Finalist Swiss Innovation Challenge 2015

The decision makers Topadur Pharma AG

Leadership Team:



Board of Directors:



Contact

Please don't hesitate to contact us if you might have any further questions

Topadur Pharma AG
 Dr. Reto Naef, Chairman
 Grabenstrasse 11a
 CH-8952 Schlieren

T +41 44 755 44 66
 M +41 79 204 77 05
info@topadur.com
www.topadur.com

Pascal Brenneisen, CEO

M +41 76 652 55 04



DISCLAIMER

This document was created by Topadur Pharma AG (hereinafter "Topadur") carefully and to the best of its knowledge and belief. However, Topadur gives no guarantee with regard to its content and completeness and does not accept any liability for losses resulting from the use of this information. The opinions expressed in this document are those of Topadur at the time of writing and are subject to change at any time and without notice. The following risks and uncertainties could influence the accuracy of this document: For example, the future financial position, capital requirements, the progress of research and development, the completion and success of clinical trials for the candidate drugs, current and future cooperation partners, as well as future developments, trends and conditions in the Industry in which Topadur operates. Should one or more of these risks or uncertainties arise or should underlying assumptions prove to be incorrect, the actual results and figures may differ materially from those stated. Unless otherwise noted, all figures are unaudited. The document is for informational purposes only and is for the exclusive use of the recipient. It does not constitute an offer or a recommendation to subscribe or otherwise acquire claims to Topadur and does not release the recipient from making his own assessment. In particular, the recipient is advised to check the information with regard to the compatibility with his own circumstances, if necessary with the help of a consultant. The only thing that is decisive for the subscription of claims is the applicable prospectus as well as the statutes and regulations of Topadur. This document may not be reproduced in whole or in part without the written consent of Topadur. It is expressly aimed only at pension funds and other tax-exempt institutions based in Switzerland that serves occupational pension purposes according to their purpose, as well as at people who manage pension funds and are supervised by FINMA. Every investment involves risks, especially those of fluctuations in value and income. Historical returns and financial market scenarios are no guarantee of current and future results. Regarding performance: There can be no guarantee that the performance of competing companies and/ or the benchmark index will be achieved or exceeded. Topadur is the issuer of securities and/or loans of any kind (including hybrids, etc.). Further information and documents are available on the website www.topadur.com and can be viewed at any time. The current annual report or factsheets can be obtained free of charge from Topadur on request.